Also, in a panel of 93 cell lines, established from breast, colon and lung cancers, lower IGFBP5 levels were indicative for a strong response to the IGF1R-specific human monoclonal antibody figitumumab (144). Here, IGFBP5 is linked to lung carcinoma.